Newsround

Newsround is a platform that provides the latest news and updates from around the world.

100+ Daily Updates
50+ Countries Covered

News Categories

Latest News

Software Stocks Are Now ‘Sentenced Before Trial,’ JPMorgan Says - Bloomberg.com
business 2026/02/04 13:30:35

Software Stocks Are Now ‘Sentenced Before Trial,’ JPMorgan Says - Bloomberg.com

Software makers, advertising agencies and investment firms were caught in another wave of selling as investors worried about the business risks they face from better artificial intelligence tools.

Bloomberg
Read Full Story
Private payrolls rose by just 22,000 in January, far short of expectations, ADP says - CNBC
business 2026/02/04 13:15:07

Private payrolls rose by just 22,000 in January, far short of expectations, ADP says - CNBC

The U.S. labor market barely budged in January, with hiring below even muted expectations.

CNBC
Read Full Story
Eli Lilly Surges 9% After Obliterating Forecasts As Mounjaro, Zepbound Sales Double - Investor's Business Daily
business 2026/02/04 13:15:00

Eli Lilly Surges 9% After Obliterating Forecasts As Mounjaro, Zepbound Sales Double - Investor's Business Daily

While Novo Nordisk is calling for a sales downfall in 2026, Eli Lilly is more upbeat.

Investor's Business Daily
Read Full Story
Wegovy maker warns of 'painful' price cuts as shares plunge - BBC
business 2026/02/04 12:27:16

Wegovy maker warns of 'painful' price cuts as shares plunge - BBC

Novo Nordisk is facing “unprecedented” price pressures, “intensifying competition” and patents expiring.

BBC News
Read Full Story
Yum Brands posts mixed quarter, Taco Bell shines - CNBC
business 2026/02/04 12:02:01

Yum Brands posts mixed quarter, Taco Bell shines - CNBC

Taco Bell’s same-store sales spiked 7% in the quarter.

CNBC
Read Full Story
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar - CNBC
business 2026/02/04 11:56:19

Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar - CNBC

Eli Lilly’s full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.

CNBC
Read Full Story